The overall quite high stability of mutational profiles under therapy is noteworthy and was most recently also described in a series of 50 matched NSCLC pairs post therapy which were analyzed for EGFR, KRAS, BRAF, PIK3CA, HER2, ALK, and MET alterations [22]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.